RxDoctor Payments Data

Marcos Hazday, MD

Cardiovascular Disease · Celebration, FLNPI 1669434809

Payments from drug & device makers

$51,368in general payments, 2019–2025

Across 298 payments — averaging $172.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lexicon Pharmaceuticals, Inc.$37K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Pfizer$4K
  • Medtronic$2K
  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$811
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$8,78061%
  • Travel & lodging$180%
  • Food & beverage$4,95635%
  • Education$5974%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,368 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$185,287
Medicare patients
386
Services billed
1,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten104$838,070
EliquisApixaban151$177,724
JardianceEmpagliflozin67$57,847
Repatha SureclickEvolocumab44$42,420
EntrestoSacubitril/Valsartan24$35,148
XareltoRivaroxaban27$27,105
Nebivolol Hcl30$2,534
Metoprolol Succinate126$2,129
Rosuvastatin Calcium109$2,038
Ranolazine ErRanolazine18$1,266
Valsartan35$1,197
Ezetimibe49$1,126
Bisoprolol Fumarate44$930
Olmesartan Medoxomil49$855
Carvedilol55$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$4,087$838,070104 claims
PfizerEliquis$3,809$177,724151 claims
Boehringer IngelheimJardiance$76$57,84767 claims
NovartisEntresto$119$35,14824 claims
Johnson & JohnsonXarelto$1,353$27,10527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Celebration

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →